8-K - Silo Pharma, Inc. (0001514183) (Filer)

SCHEDULE 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

EFFECT - Silo Pharma, Inc. (0001514183) (Filer)

424B3 - Silo Pharma, Inc. (0001514183) (Filer)

SCHEDULE 13G - Silo Pharma, Inc. (0001514183) (Subject)

10-Q - Silo Pharma, Inc. (0001514183) (Filer)

S-1 - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements.   The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as repo

SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder (PTSD). The allowed application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," strengthens Silo's growing intellectual-proper

Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent ("LOI") with Allucent (US) LLC ("Allucent"), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subject

SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Allucent, a global full-service clinical research organization (CRO), to support the Company's final preparations and planned submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD. The Company currently expects to submit the IND in 2026 and commence its first-in-human (FIH) SPC-15 trial subsequent to FDA approval. "We believe that a partnership with All

Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo's objective of generating yield while maintaining a hedge against downside risk New York, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Alphaledger/Simplify Target 12% Distribution Fund LLC (the "Alphaledger T12 Fund") as a core component of its real-world asset (RWA) investment strategy on the Solana blockchain. This strategic allocation aligns with Silo's approac

Significant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to commence before year-end SARASOTA, FL, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a comprehensive update detailing progress for lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety, and key achievements under Silo's new digital assets treasury platform launched in August 2025. Biopharmaceutical Platform: Silo i

SARASOTA, FL, Oct. 08, 2025 (GLOBE NEWSWIRE) --   Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of Bitcoin under its crypto reserve strategy targeting multi-chain asset growth. "Silo's latest strategic crypto purchase signals our conviction in Bitcoin as both store of value and a hedge against general financial market volatility," said Eric Weisblum, CEO of Silo. "Overall, the four crypto investments we have made so far underscore our Company's confidence in the growing adoption and value creation opportunities available through a digital asset treasury

Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that are immediately exer

SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that wil

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)